Core Viewpoint - Shanghai Fosun Pharmaceutical (Group) Co., Ltd. plans to spin off its subsidiary, Fosun Antigen (Chengdu) Biopharmaceutical Co., Ltd., for a listing on the Hong Kong Stock Exchange, which is expected to maintain the company's control over the subsidiary after the split [1][6]. Group 1: Spin-off Details - The board of directors approved the spin-off proposal during a meeting held on January 22, 2026, with unanimous support from all directors [5][7]. - The spin-off is subject to various approvals, including from the company's shareholders and regulatory bodies, which introduces uncertainty regarding the timeline and feasibility of the listing [2][9]. Group 2: Financial and Operational Aspects - Fosun Antigen has reported net profits of RMB 3.731 billion, RMB 2.011 billion, and RMB 2.314 billion for the years 2022, 2023, and 2024 respectively, indicating consistent profitability over the last three years [21]. - The cumulative net profit attributable to the parent company, after excluding the subsidiary's losses, is RMB 8.076 billion, exceeding the required RMB 600 million [21][22]. Group 3: Strategic Rationale - The spin-off aims to enhance the focus on the vaccine business, which is positioned as a core area of growth amid increasing demand for innovative vaccines [40][41]. - By establishing Fosun Antigen as an independent entity, the company seeks to optimize resource allocation and improve operational efficiency, thereby enhancing competitiveness in the vaccine market [42][43]. Group 4: Market Position and Future Prospects - The spin-off is expected to unlock the valuation potential of Fosun Antigen, allowing for clearer financial analysis and potentially better market pricing [44]. - The move is aligned with the company's internationalization strategy, leveraging Hong Kong's status as a financial hub to attract global investment and partnerships [45].

Major Events - UBTECH (09880) plans to invest 300 million yuan to establish a partnership for investments in the smart robotics industry chain [1] - Tian Ge Interactive (01980) received a 1.41% discount from Sina Hong Kong for a partial tender offer to acquire 32.5 million shares, with trading resuming on January 22 [1] - Fosun Pharma (02196) received approval for the drug registration application of heavy tartrate norepinephrine injection [1] - Valiant (09887) received orphan drug designation (ODD) from the European Commission for Valiant™ for the treatment of extra-pulmonary neuroendocrine carcinoma [1] - GCL-Poly Energy (01050) secured orders for AI giant server enclosures, accelerating ASIC business production, and commenced construction of a new base in Thailand [1] - China Rare Earth Holdings (03788) plans to raise approximately 783 million HKD to support the development of the Mt Bundy gold mine project [1] - Nanshan Aluminum International (02610) plans to place 31 million shares, aiming to raise approximately 1.9868 billion HKD [1] - Qiming Medical-B (02500) reported a patent infringement lawsuit against Edwards by Cardiovalve Ltd. and MTH IP, L.P. regarding US Patent No. 385 [1] - Minmetals Resources (01208) expects total copper production of 506,900 tons in 2025, a year-on-year increase of 27% [1] - Prudential (02378) invested approximately 375 million USD to increase its stake in PAMB to 70% [1] - Nocoda Technology (00519) successfully implemented innovative smart handling robots in Hong Kong public housing estates [1] - Idali Holdings (00720) B-ON Global S.àr.l. plans to acquire 1.3 billion shares of the company, becoming the major shareholder [1] Bonds and Notes - China Shipbuilding Leasing (03877) subsidiary plans to issue 2.338 billion HKD convertible bonds [2] Buybacks/Reductions - China Communications Construction (01800) repurchased 1.06837 million HKD worth of 1.2588 million A-shares on January 22 [2] - Kuaishou-W (01024) spent approximately 29.9714 million HKD to repurchase 380,000 shares on January 22 [2] - Xiaomi Group-W (01810) repurchased shares worth 201 million HKD, acquiring 5.7138 million shares on January 22 [2] - Xiaomi Group-W (01810) plans to repurchase up to 2.5 billion HKD of Class B ordinary shares [2] - Sanhua Intelligent Control (02050) controlling shareholders, directors, and executives plan to collectively reduce their holdings by up to approximately 10.2037 million A-shares [2] Operating Performance - AsiaInfo Technologies (01675) expects to turn cash flow positive by 2025, driven by rapid growth in AI business [2] - Zhaoyi Innovation (03986) issued a profit warning, expecting a net profit of approximately 1.61 billion yuan in 2025, a year-on-year increase of about 46% [2] - MicroPort Medical (00853) issued a profit warning, expecting a net profit of no less than 20 million USD in 2025, turning profitable year-on-year [2]

Core Viewpoint - Fosun Pharma's subsidiary, Jinzhou Aohong Pharmaceutical, has received approval from the National Medical Products Administration for the registration of a new drug, heavy tartrate norepinephrine injection, which is indicated for the treatment of acute hypotension and as an auxiliary treatment for cardiac arrest [1] Group 1 - The approved drug is indicated for restoring blood pressure in acute hypotensive states, assisting in cardiac arrest treatment, and maintaining blood pressure after cardiac arrest recovery [1] - The drug can also be used as an auxiliary treatment for shock due to insufficient blood volume, helping to temporarily maintain cerebral and coronary perfusion until volume resuscitation takes effect [1] - The drug is classified as a Class 3 chemical drug and is produced by Jinzhou Aohong Pharmaceutical [1]

Core Viewpoint - Fosun Pharma's subsidiary, Jinzhou Aohong Pharmaceutical, has received approval from the National Medical Products Administration for the registration of a new drug, heavy tartrate norepinephrine injection, which is indicated for acute hypotensive states and other critical conditions [1] Group 1 - The approved drug is indicated for restoring blood pressure in acute hypotensive states, assisting in treatment during cardiac arrest, and maintaining blood pressure post-cardiac arrest [1] - The drug can also be used as an auxiliary treatment for shock due to insufficient blood volume, helping to temporarily maintain cerebral and coronary perfusion until volume resuscitation takes effect [1] - The drug is classified as a Class 3 chemical drug and is produced by Jinzhou Aohong Pharmaceutical [1]

Core Viewpoint - Fosun Pharma's subsidiary, Jinzhou Aohong Pharmaceutical, has received approval from the National Medical Products Administration for the registration of a drug, which is indicated for the treatment of acute hypotensive states and as an auxiliary treatment for cardiac arrest [1] Group 1 - The approved drug is a formulation of dexmedetomidine hydrochloride injection, which is used to restore blood pressure in acute hypotensive states [1] - The drug can also assist in the treatment of cardiac arrest and maintain blood pressure after resuscitation [1] - It serves as an auxiliary treatment for shock caused by insufficient blood volume, temporarily maintaining cerebral and coronary perfusion until volume resuscitation takes effect [1]

Core Viewpoint - Fosun Pharma (600196.SH) announced that its subsidiary, Jinzhou Aohong Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the drug registration application of Dextroamphetamine Injection, which is indicated for the treatment of acute hypotensive states and as an auxiliary treatment for cardiac arrest [1] Group 1 - The approved indication for the drug includes restoring blood pressure in acute hypotensive states [1] - The drug can also be used as an auxiliary treatment for cardiac arrest and to maintain blood pressure after cardiac resuscitation [1] - It serves as an auxiliary treatment for shock due to insufficient blood volume, helping to temporarily maintain cerebral and coronary perfusion until volume resuscitation takes effect [1]

Core Viewpoint - Fosun Pharma's subsidiary, Jinzhou Aohong Pharmaceutical, has received approval from the National Medical Products Administration for the registration of a drug, norepinephrine injection, which is indicated for the treatment of acute hypotension and as an auxiliary treatment for cardiac arrest [1] Group 1 - The approved drug is indicated for restoring blood pressure in acute hypotensive states [1] - It can also be used as an auxiliary treatment for cardiac arrest and maintaining blood pressure after resuscitation [1] - The drug serves as an auxiliary treatment for shock due to hypovolemia, helping to temporarily maintain cerebral and coronary perfusion until volume resuscitation takes effect [1]

Core Viewpoint - Fosun Pharma's subsidiary, Jinzhou Aohong Pharmaceutical Co., has received approval from the National Medical Products Administration for the registration of a drug, which is indicated for the treatment of acute hypotensive states and as an auxiliary treatment for cardiac arrest [1] Group 1 - The approved drug is a formulation of dexmedetomidine hydrochloride injection [1] - The indications for the drug include restoring blood pressure in acute hypotensive states, assisting in cardiac arrest treatment, and maintaining blood pressure post-cardiac arrest [1] - The drug is also indicated as an auxiliary treatment for shock due to insufficient blood volume, aimed at temporarily maintaining cerebral and coronary perfusion until volume resuscitation takes effect [1]

Core Viewpoint - Fosun Pharma's subsidiary, Jinzhou Aohong Pharmaceutical, has received approval from the National Medical Products Administration for the registration of a drug, which is indicated for the treatment of acute hypotensive states and can assist in the treatment of cardiac arrest and shock [1] Group 1 - The approved drug is a formulation of norepinephrine bitartrate injection [1] - The indications for the drug include restoring blood pressure in acute hypotensive states, assisting in cardiac arrest treatment, and maintaining blood pressure post-cardiac arrest [1] - The drug is also indicated as an auxiliary treatment for shock due to hypovolemia, aimed at temporarily maintaining cerebral and coronary perfusion until volume resuscitation takes effect [1]

Core Viewpoint - The approval of the drug by the National Medical Products Administration marks a significant milestone for the company, indicating its successful entry into the market for critical care medications [1] Group 1: Drug Approval and Indications - The company's subsidiary, Jinzhou Aohong Pharmaceutical Co., Ltd., received approval for the registration of the drug, which is a formulation of dexmedetomidine injection [1] - The approved indications for the drug include the restoration of blood pressure in acute hypotensive states, auxiliary treatment for cardiac arrest, and maintenance of blood pressure post-cardiac arrest [1] Group 2: Research and Development Investment - The drug is developed independently by the company, with a cumulative R&D investment of approximately RMB 8.74 million expected by December 2025 [1] Group 3: Market Potential - According to IQVIA CHPA data, the projected sales of the drug in China for 2024 are estimated to be around RMB 1.811 billion [1]